Panobinostat (LBH589)
by Jessica Langholtz
Published: Dec 3, 2009 3:29 pm
Published: Dec 3, 2009 3:29 pm
| Brand Name: | |
| Generic Name: | panobinostat |
| Code Name: | LBH589 |
| Company: | Novartis |
| FDA Clinical Phase: | 1 |
Description:
Panobinostat, which is a potent histone deacetylase (HDAC) inhibitor, selectively targets tumor cells for cell death. In Phase 1 trials, panobinostat was highly active as a single agent treatment for several types of cancer, including multiple myeloma, Hodgkin’s lymphoma, acute myeloid leukemia, and prostate cancer. Additional clinical trials are currently underway to examine the efficacy and safety profile of panobinostat.
Clinical Trials:
Currently, there are several open clinical studies involving panobinostat.
Official Web site for panobinostat: http://www.novartisoncology.com/research-innovation/pipeline/panobinostat.jsp
Updated December 3, 2009
Related Articles:
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
- Panobinostat Combinations Show Therapeutic Benefit In Advanced Multiple Myeloma (ASCO 2010)
- New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
- Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
- Beacon NewsFlashes – April 22, 2009
Leave a comment